Effects of SGLT2 Inhibitors beyond Glycemic Control-Focus on Myocardial SGLT1

Selective sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of hospitalization for heart failure in patients with or without type 2 diabetes (T2DM) in large-scale clinical trials. The exact mechanism of action is currently unclear. The dual SGLT1/2 inhibitor sotagliflozin not only r...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2021-09, Vol.22 (18), p.9852
Main Authors: Sayour, Alex Ali, Ruppert, Mihály, Oláh, Attila, Benke, Kálmán, Barta, Bálint András, Zsáry, Eszter, Merkely, Béla, Radovits, Tamás
Format: Article
Language:English
Subjects:
Cardiomyocytes
Cardiomyopathy
Cerebral infarction
Clinical trials
Congestive heart failure
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetic Cardiomyopathies - prevention & control
dual SGLT1/2 inhibitor
Ejection fraction
empagliflozin
Glucose
Heart - drug effects
heart failure
Hospitalization
Humans
Inhibitors
Kidneys
Myocardial infarction
myocardial ischemia
Myocardium - metabolism
Patients
Review
SGLT2 inhibitor
Sodium-Glucose Transporter 1 - antagonists & inhibitors
Sodium-Glucose Transporter 1 - metabolism
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
sodium–glucose cotransporter 1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Selective sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of hospitalization for heart failure in patients with or without type 2 diabetes (T2DM) in large-scale clinical trials. The exact mechanism of action is currently unclear. The dual SGLT1/2 inhibitor sotagliflozin not only reduced hospitalization for HF in patients with T2DM, but also lowered the risk of myocardial infarction and stroke, suggesting a possible additional benefit related to SGLT1 inhibition. In fact, several preclinical studies suggest that SGLT1 plays an important role in cardiac pathophysiological processes. In this review, our aim is to establish the clinical significance of myocardial SGLT1 inhibition through reviewing basic research studies in the context of SGLT2 inhibitor trials.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms22189852